Development of vaccines for high-risk ductal carcinoma in situ of the breast

被引：24

作者：

Czerniecki, Brian J.

Roses, Robert E.

Koski, Gary K.

机构：

[1] Univ Penn, Harrison Dept Res, Dept Surg, Philadelphia, PA 19104 USA

[2] Cleveland Clin Fdn, Surg Res Ctr, Cleveland, OH 44195 USA

来源：

CANCER RESEARCH | 2007年 / 67卷 / 14期

关键词：

D O I：

10.1158/0008-5472.CAN-07-0878

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Certain ductal carcinoma in situ (DCIS) lesions overexpress the HER-2/neu receptor at this early stage of breast cancer development. Recently, we showed that a HER-2-targeted dendritic cell vaccine could be used to eliminate HER-2-overexpressing cells in patients that harbor these high-risk DCIS lesions. Our findings suggest that vaccinating such patients might diminish the risk of recurrence, protect against the development of invasive breast cancer, and minimize morbidity associated with current treatments. We discuss several implications of this work for developing effective cancer vaccines.

引用

收藏

页码：6531 / 6534

页数：4

相关论文

共 21 条

[1]

Histological and biological evolution of human premalignant breast disease [J].

Allred, DC ;

Mohsin, SK ;

Fuqua, SAW .

ENDOCRINE-RELATED CANCER, 2001, 8 (01) :47-61

[2]

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast [J].

Barnes, NLP ;

Khavari, S ;

Boland, GP ;

Cramer, A ;

Knox, WF ;

Bundred, NJ .

CLINICAL CANCER RESEARCH, 2005, 11 (06) :2163-2168

[3]

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion [J].

Czerniecki, Brian J. ;

Koski, Gary K. ;

Koldovsky, Ursula ;

Xu, Shuwen ;

Cohen, Peter A. ;

Mick, Rosemarie ;

Nisenbaum, Harvey ;

Pasha, Terry ;

Xu, Min ;

Fox, Kevin R. ;

Weinstein, Susan ;

Orel, Susan G. ;

Vonderheide, Robert ;

Coukos, George ;

DeMichele, Angela ;

Araujo, Louis ;

Spitz, Francis R. ;

Rosen, Mark ;

Levine, Bruce L. ;

June, Carl ;

Zhang, Paul J. .

CANCER RESEARCH, 2007, 67 (04) :1842-1852

[4]

Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].

Disis, ML ;

Gooley, TA ;

Rinn, K ;

Davis, D ;

Piepkorn, M ;

Cheever, MA ;

Knutson, KL ;

Schiffman, K .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632

[5]

Cancer immunoediting: from immunosurveillance to tumor escape [J].

Dunn, GP ;

Bruce, AT ;

Ikeda, H ;

Old, LJ ;

Schreiber, RD .

NATURE IMMUNOLOGY, 2002, 3 (11) :991-998

[6]

Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO

[7]

2-Y

[8]

Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (Herceptin) [J].

Gonzalez, Ricardo J. ;

Buzdar, Aman U. ;

Symmans, W. Fraser ;

Yen, Tina W. ;

Broglio, Kristine R. ;

Lucci, Anthony ;

Esteva, Francisco J. ;

Yin, Guosheng ;

Kuerer, Henry M. .

BREAST JOURNAL, 2007, 13 (01) :72-75

[9]

Neoadjuvant hormonal therapy for ductal carcinoma in situ: Trial design and preliminary results [J].

Hwang, ES ;

Esserman, L .

ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (01) :37S-43S

[10]

Kerlikowske K, 1997, JNCI-J NATL CANCER I, V89, P76, DOI 10.1093/jnci/89.1.76